Search Results

Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023.

Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in Xenopus laevis.

AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced that Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer.

Juvenescence, a life sciences company targeting the intrinsic mechanisms of aging, announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life.

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team.

AgeX Therapeutics, Inc. reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human longevity, is pleased to announce the appointment of Dr. Jean-Christophe Renondin to its Main Board of Directors, and of Dr. David Roblin and Dr. Steve Felstead to its Senior Leadership Team.

Juvenescence Limited announces that Juvenescence.AI, its joint venture with Insilico Medicine, Inc. (“Insilico”), has licensed its first compound family for clinical development.